Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration The Guardian - UK · Feb 5, 2025
AstraZeneca’s U-turn on £450m Speke expansion ‘deeply disappointing’, says minister Chris Bryant says reduction of government support was linked to change in drugmaker’s proposed investment The Guardian - UK · Feb 3, 2025
AstraZeneca investment deal ‘didn’t add up for UK taxpayer’, says minister Science minister Sir Chris Bryant said the Government feels regretful about the plan being ditched and ‘would prefer to have got this over the line’. Evening Standard · Feb 3, 2025
AstraZeneca’s £450m Speke U-turn looks terrible for a pro-growth government It seems bizarre that ministers and UK’s largest company cannot complete investment in vital life sciences sector The Guardian - UK · Feb 3, 2025
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp? MarketBeat · Feb 3, 2025
AbbVie Investors Trigger Trend-Following Signal: Time to Load Up AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025. MarketBeat · Jan 31, 2025
AstraZeneca axes £450m vaccine plant in Liverpool, blaming state funding cut Days after Rachel Reeves highlighted life sciences as UK strength, firm decides against site expansion The Guardian - UK · Jan 31, 2025
Suspected drug deaths in Scotland down by 10 per cent, latest figures show Suspected drugs deaths have fallen by 10 per cent in the latest quarterly data, with drug-related attendances at A&E seeing a similar decrease. The National (Scotland) · Jan 28, 2025
Vivek Ramaswamy To Run For Ohio Governor In 2026 Vivek Ramaswamy, with support from JD Vance's team, gears up for the 2026 Ohio gubernatorial race in a competitive GOP landscape. Top News · Jan 27, 2025
Wegovy maker Novo Nordisk rebuked by watchdog over failure to disclose payments to UK health groups Danish drug giant found to have failed to accurately report spending even after admitting to errors The Guardian - UK · Jan 26, 2025
Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know. Kiplinger · Jan 24, 2025
Sackler family to pay $6.5 billion for their role in ‘fueling’ opioid epidemic which has killed hundreds of thousands Sackler family, who owned pharmaceutical company Purdue Pharma, will no longer be in control of the company or permitted to sell opioids if the new settlement plan is approved The Independent UK · Jan 23, 2025
New York AG Blasts Sackler Family While Announcing $7.4 Billion Purdue Pharma Settlement: 'No Amount of Money Will Ever Fully Repair The Damage They Caused' New York's AG shared news of The Sackler family and Purdue Pharma settlement, while stating "no amount of money" could reverse the destruction caused. Latin Times · Jan 23, 2025
Purdue Pharma and owners to pay $7.4 billion in settlement to lawsuits over the toll of OxyContin Members of the Sackler family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion to settle lawsuits over the toll of the powerful prescription painkiller The Independent UK · Jan 23, 2025
International Business Times · Jan 23, 2025 Sacklers, Purdue To Pay $7.4 Bn Over Opioid Crisis Several US states have reached a $7.4 billion settlement with the Sackler family and their pharmaceutical company Purdue over the opioid crisis that has ravaged the lives of millions of Americans, officials said Thursday.
The Guardian - US · Jan 23, 2025 Purdue Pharma and Sacklers reach new $7.4bn settlement over opioids crisis Settlement resolves thousands of lawsuits alleging Oxycontin caused addiction crisis
International Business Times UK · Jan 22, 2025 'It's Out of Control': UnitedHealth Group and Peers Charged Americans 1000% More for Drugs FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.
MarketBeat · Jan 20, 2025 There May Still Be Time to Get in on These 3 Trending Biotechs Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
MarketBeat · Jan 20, 2025 Hims & Hers Health: A Stock to Trade or Own? HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.
Kiplinger · Jan 17, 2025 Medicare Price Negotiations To Continue Under the Trump Administration The Centers for Medicare & Medicaid Services plans to negotiate the prices for 15 new drugs, although it says its seeking "greater transparency" in price talks.
MarketBeat · Jan 17, 2025 Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025
MarketBeat · Jan 17, 2025 Is Johnson & Johnson Stock Set to Reward Long-Term Holders? JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive
Latin Times · Jan 16, 2025 UnitedHealth Is Price Gouging Cancer Patients by Overcharging 'Thousands of Percent' for Live-Saving Meds, Pocketing Extra Billions: Feds The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases the cost of such medication exponentially.
MarketBeat · Jan 16, 2025 Vertex's Pain Drug: Big Pharma's Next Major Success? Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.
StockNews.com · Jan 15, 2025 3 Niche Biotech Stocks Redefining Innovation The biotech market offers great investment potential due to innovative advancements in genetic profiling, biologics, CRISPR technology, and rare disease treatments driving strong demand and growth. Therefore, investing in strong biotech stocks like Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR) could be wise. Read on.